Pharmaceuticals
Kelun-Biotech to Present Multiple Study Results at ESMO 2026
CHENGDU, China, Oct. 13, 2026 /PRNewswire/ -- The 2026 European Society for Medical Oncology (ESMO) Congress will be held in Madrid, Spain, from October 23 to 27. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) will present results from multiple clini...
2026-10-13 19:23
2850
Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China
Hiteck grants Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ: NBP), exclusive worldwide rights, excluding Greater China, to develop and commercialize HT006.2.2 Hiteck retains all rights in Greater China, where a Phase 1b study in severe neurotrophic keratitis...
2026-10-13 19:00
2894
Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases
SANTA BARBARA, Calif., Oct. 13, 2026 /PRNewswire/ -- Rona Therapeutics today announced it has granted Roche (SIX: RO, ROG; OTCQX: RHHBY) an exclusive worldwide license for Rona's investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7) utilizing the company's proprietary ext...
2026-10-13 15:00
6869
Fosun International Wins Five Awards at The Asset Corporate Sustainability Leadership Awards 2026, Upgraded to Platinum
HONG KONG, Oct. 13, 2026 /PRNewswire/ -- Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) today announced that it has been awarded the prestigious"Corporate Sustainability Leadership Awards 2026 – Platinum Award" by The Asset, a leading Asia-Pacific fi...
2026-10-13 12:46
8842
ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention
SHANGHAI, Oct. 13, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new drug (IND) application for AK0406, a long-acting antiviral drug-Fc conjugate (AFC), enabling the company...
2026-10-13 09:00
3317
GCCL and LabConnect Sign MOU to Expand Global Clinical Trial Collaboration
Linking North American and Asia-Pacific Capabilities to Support Joint Sales and Project Execution SEOUL, South Korea and RALEIGH, N.C., Oct. 13, 2026 /PRNewswire/ -- GCCL, a South Korea-based leading global clinical trial central laboratory represented by CEO Kwan-goo Cho, announced today that i...
2026-10-13 08:15
3607
SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease
LUCERNE, Switzerland and NEW DELHI, Oct. 13, 2026 /PRNewswire/ -- The SPARX Global Randomized Controlled Trial (RCT) has been officially initiated, marking the launch of the multinational randomized trial evaluating a drug-coated balloon (DCB)-first strategy against contemporary drug-eluting sten...
2026-10-13 02:11
3399
T-MAXIMUM's B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer
BEIJING, Oct. 12, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL ("T-MAXIMUM") today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate a Phase 2 clinical study of MT027, its internally developed, B7-H3-targeted universal (allogeneic) CAR-T therapy, for ...
2026-10-12 18:50
2181
Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 2026
* New data show favorable outcomes with subcutaneous infliximab following intravenous infliximab interruption, regardless of prior antibody status, in adult patients with moderate to severely active Crohn's disease and ulcerative colitis * Late-breaking analysis shows significantly higher rat...
2026-10-12 01:00
4231
New Opportunities for Global Cooperation: Kexing Biopharm Shines at CPHI Milan 2026
MILAN, Oct. 10, 2026 /PRNewswire/ -- From October 06 to 08, 2026, Kexing Biopharm (688136.SH) exhibited at CPHI Milan 2026, showcasing its global innovative drug pipeline, co-developed biosimilars, and a broad portfolio of products commercialized in overseas markets. During the event, the Company...
2026-10-10 16:06
5126
First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer
HONG KONG, Oct. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as monotherapy in the neoa...
2026-10-10 12:41
3498
Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026
SHANGHAI and HONG KONG, Oct. 9, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune di...
2026-10-09 11:22
5083
Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development
* Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational Lead, Cancer Vaccines at Moderna, join Everest Medicines * Appointments support continued advancement of Everest's mRNA pip...
2026-10-09 10:15
6283
Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease
* SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid Eye Disease(TED) SAN FRANCISCO and SUZHOU, China, Oct. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX...
2026-10-09 08:00
4373
Telix to Host Capital Markets Day in Melbourne on November 4, 2026
MELBOURNE, Australia and INDIANAPOLIS, Oct. 9, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announced that it will host a Capital Markets Day in Melbourne, Australia, on Wednesday, November 4, 2026, from 9:00 a.m. to 12:30 p.m. (AEDT). Institutional i...
2026-10-09 04:00
2629
China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering
TAIZHOU, China, Oct. 8, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 8,000,000 Class A ordinary shares of the co...
2026-10-08 21:22
6931
SECuRE update: recruitment target of the Cohort Expansion Main Group achieved
SYDNEY, Oct. 8, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the recruitment t...
2026-10-08 21:01
3055
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS
2026-10-08 21:00
3545
Rockwell Automation and Industry Leaders Launch the Digital CMC Consortium to Accelerate Digital Transformation in Pharmaceutical Development
New industry collaboration addresses pharma's most complex development
challenges and expedites patient access to breakthrough therapies
MILWAUKEE, Oct. 8, 2026 /PRNewswire/ -- Rockwell Automation, Inc.
2026-10-08 21:00
4429
Nuevocor Doses First Patient in SUNBEAM-LMNA Phase 1/2 Trial and Receives FDA Fast Track Designation for NVC-001 in LMNA Dilated Cardiomyopathy
NVC-001 is designed to target the mechanobiological root cause of LMNA dilated cardiomyopathy and has disease-modifying potential SINGAPORE, PARIS and PHILADELPHIA, Oct. 8, 2026 /PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company pioneering mechanobiology-targeted therapies designed...
2026-10-08 19:30
6318
Week's Top Stories
Most Reposted
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1168 media titles]
2026-11-02 20:00OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1129 media titles]
2026-11-05 06:52Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1082 media titles]
2026-11-03 22:00Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update
[Picked up by 1079 media titles]
2026-10-30 22:34
H.E. Ahmed Al-Khateeb, Saudi Minister of Tourism, Inaugurates Saudi Land at WTM London 2026, Reinforcing Saudi's Commitment to Global Travel Trade
[Picked up by 1067 media titles]
2026-11-04 07:31
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
59666
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
54717
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
52721
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
22167
Lorikeet Dreamweaver enables businesses to give every customer an AI account manager
2026-11-04 22:00
17491